CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Oxaliplatin +1 moredrug
Likely dose
Oxaliplatin 100 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00859469
NCT00859469Phase 2Completed
CompareCT.gov

Oxaliplatin (Eloxatin®) Plus Gemcitabine as First or Second-line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial

Columbia University·interventional·Posted Mar 11, 2009·Updated Oct 30, 2019

In Brief

A Phase 2 clinical trial evaluating Oxaliplatin and Gemcitabine for Mesothelioma. Completed, enrolled 29 participants across 1 site.

Detailed Summary

In patients with pleural or peritoneal mesothelioma, what is the response rate to combined Oxaliplatin (ELOXATIN®) and Gemcitabine chemotherapy?

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMesothelioma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 11, 2009
Enrollment StartApr 1, 2004
Primary CompletionMar 1, 2009
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 17.3 years ago

Interventions

Oxaliplatindrug

Oxaliplatin 100 mg/m2 IV infusion for 2 hours

Gemcitabinedrug

Gemcitabine 1000mg/m2 IV infusion for 90 minutes